The limited effectiveness of T cell-based immune checkpoint blockade (ICB) therapy in most patients with pancreatic ductal adenocarcinoma (PDAC) is largely due to poor CD8<sup>+</sup> T cell infiltration and a highly immunosuppressive microenvironment driven by excessive myeloid cell accumulation. This evidence concerns the gene CD8A and pancreatic ductal adenocarcinoma.